{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:14Z","timestamp":1790916794580,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":167,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101293","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:01:38Z","timestamp":1781870498000},"page":"101293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Theranostic strategies in prostate cancer: Advances in PSMA PET imaging and radioligand therapy"],"prefix":"10.1016","volume":"48","author":[{"given":"Talal","family":"Al-Assil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5467-7491","authenticated-orcid":false,"given":"Nazmul","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Seneriches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jena","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash Rezazadeh","family":"Kalebasty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2026.101293_bib0001","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J. Urol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101293_bib0002","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4. 2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101293_bib0003","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum Imaging strategies for advanced prostate cancer: ASCO guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101293_bib0004","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur. Urol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101293_bib0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","article-title":"The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer","volume":"19","author":"Wang","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ctarc.2026.101293_bib0006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.canlet.2021.08.033","article-title":"Chemotherapy in metastatic castration-resistant prostate cancer: current scenario and future perspectives","volume":"523","author":"Ruiz de Porras","year":"2021","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101293_bib0007","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.tips.2016.03.003","article-title":"Improving taxane-based chemotherapy in castration-resistant prostate cancer","volume":"37","author":"Kroon","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"Suppl 2","key":"10.1016\/j.ctarc.2026.101293_bib0008","doi-asserted-by":"crossref","first-page":"67S","DOI":"10.2967\/jnumed.116.186767","article-title":"Prostate-specific membrane antigen ligands for imaging and therapy","volume":"58","author":"Eiber","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101293_bib0009","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2967\/jnumed.120.257238","article-title":"Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer","volume":"62","author":"Farolfi","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101293_bib0010","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101293_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/RLU.0000000000004919","article-title":"PSMA radioligand therapy in prostate cancer: where are we and where are we heading?","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101293_bib0012","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/JU.0000000000002457","article-title":"Imaging prostate cancer: clinical utility of prostate-specific membrane antigen","volume":"207","author":"Kuppermann","year":"2022","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101293_bib0013","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.117.191874","article-title":"Why targeting PSMA is a game changer in the management of prostate cancer","volume":"59","author":"Donin","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101293_bib0014","doi-asserted-by":"crossref","first-page":"947","DOI":"10.2967\/jnumed.116.185538","article-title":"PSA-stratified performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer","volume":"58","author":"Dietlein","year":"2017","journal-title":"J. Nucl. Med."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101293_bib0015","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","article-title":"Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis","volume":"27","author":"Huang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101293_bib0016","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3892\/ol.2024.14321","article-title":"Diagnostic performance of 18F\u2011DCFPyL PET vs. 68Ga\u2011PSMA PET\/CT in patients with suspected prostate cancer: a systemic review and meta\u2011analysis","volume":"27","author":"Jiang","year":"2024","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101293_bib0017","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0018","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.2967\/jnumed.121.263440","article-title":"Utility of 18F-rhPSMA-7.3 PET for imaging of primary prostate cancer and preoperative efficacy in N-staging of unfavorable intermediate- to very high-risk patients validated by histopathology","volume":"63","author":"Langbein","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"Suppl 6","key":"10.1016\/j.ctarc.2026.101293_bib0019","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2023.41.6_suppl.318","article-title":"Positron emission tomography of patients with confirmed prostate cancer using 64Cu-SAR-bisPSMA","volume":"41","author":"Emmett","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0020","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 Vipivotide Tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101293_bib0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.ctarc.2026.101293_bib0022","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.22.01865","article-title":"Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer: ASCO rapid recommendation","volume":"40","author":"Garje","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.ctarc.2026.101293_bib0023","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR Phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101293_bib0024","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101293_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/OP.22.00753","volume":"19","author":"Garje","year":"2023","journal-title":"JCO Oncol. Pract."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101293_bib0026","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s00259-024-06932-2","article-title":"Assessment of the therapeutic efficacy of [177Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-na\u00efve patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"52","author":"Almeida","year":"2025","journal-title":"Eur J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101293_bib0027","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3390\/ph18081215","article-title":"Targeted alpha therapy: exploring the clinical insights into [225Ac]Ac-PSMA and its relevance compared with [177Lu]Lu-PSMA in advanced prostate cancer management","volume":"18","author":"Jalloul","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101293_bib0028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101293_bib0029","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","article-title":"Clinical and biological features of neuroendocrine prostate cancer","volume":"23","author":"Yamada","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101293_bib0030","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101293_bib0031","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","article-title":"Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer","volume":"4","author":"Bakht","year":"2023","journal-title":"Nat. Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101293_bib0032","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2967\/jnumed.119.231068","article-title":"Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for 18F-FDG imaging of PSMA-suppressed tumors","volume":"61","author":"Bakht","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0033","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1007\/s00330-023-09619-8","article-title":"Even-Sapir E. PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies","volume":"33","author":"Cohen","year":"2023","journal-title":"Eur. Radiol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0034","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","article-title":"Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA","volume":"44","author":"Bozkurt","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101293_bib0035","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2967\/jnumed.122.264860","article-title":"SNMMI procedure standard\/EANM practice guideline for SSTR PET: imaging neuroendocrine tumors","volume":"64","author":"Hope","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0036","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.121.263221","article-title":"Molecular imaging of neuroendocrine prostate cancer by targeting delta-like Ligand 3","volume":"63","author":"Korsen","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101293_bib0037","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.3390\/cancers15174404","article-title":"PET\/CT and conventional imaging for the assessment of neuroendocrine prostate cancer: a systematic review","volume":"15","author":"Dondi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101293_bib0038","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ctarc.2026.101293_bib0039","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/medicina61081341","article-title":"Efficacy and safety of Radioligand therapy with actinium-225 DOTATATE in patients with advanced, metastatic or inoperable neuroendocrine neoplasms: a systematic review and meta-analysis","volume":"61","author":"Rizzo","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"4_suppl","key":"10.1016\/j.ctarc.2026.101293_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2024.42.4_suppl.31","article-title":"Prognostic value of FDG, PSMA, and DOTATATE uptake on PET imaging in metastatic castration-resistant prostate cancer (mCRPC)","volume":"42","author":"Pouliot","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101293_bib0041","article-title":"Diagnostic value of dual-tracer PET\/CT with [18F]FDG and PSMA ligands in prostate cancer: an updated systematic review","volume":"12","author":"Iacovitti","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2026.101293_bib0042","doi-asserted-by":"crossref","first-page":"TPS264","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS264","article-title":"Study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 radionuclide therapy prior to radical prostatectomy in men with high-risk localized prostate cancer (LuTectomy study)","volume":"39","author":"Alghazo","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0043","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00259-024-06726-6","article-title":"Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties","volume":"51","author":"Hou","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ctarc.2026.101293_bib0044","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2967\/jnumed.124.268959","article-title":"Dansylated amino acid-modified long-acting PSMA derivatives 68Ga\/177Lu-LNC1011 as prostate cancer theranostics","volume":"66","author":"Yang","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0045","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2967\/jnumed.123.267126","article-title":"61Cu-PSMA-targeted PET for prostate cancer: from radiotracer development to first-in-Human imaging","volume":"65","author":"Basaco Bernabeu","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101293_bib0046","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1007\/s00259-025-07155-9","article-title":"Development of [225Ac]Ac\u2011LNC1011 for targeted alpha-radionuclide therapy of prostate cancer","volume":"24","author":"Wen","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ctarc.2026.101293_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116545","article-title":"Synthesis and preclinical evaluation of 68Ga-labeled PSMA tracers with improved pharmacological properties","volume":"274","author":"Hou","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ctarc.2026.101293_bib0048","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.3390\/jcm13164585","article-title":"Investigating combination therapy: the role of lutetium-177 PSMA-617 radioligand therapy and androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer","volume":"13","author":"K\u0131n\u0131ko\u011flu","year":"2024","journal-title":"J. Clin. Med."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101293_bib0049","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/pros.24219","article-title":"Combined 177 Lu-PSMA-617 PRLT and abiraterone acetate versus 177 Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: an observational study comparing the response and durability","volume":"81","author":"Suman","year":"2021","journal-title":"Prostate"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101293_bib0050","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s11912-023-01458-6","article-title":"Towards improving the efficacy of PSMA-targeting radionuclide therapy for late-stage prostate cancer-combination strategies","volume":"25","author":"Arbuznikova","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101293_bib0051","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2967\/jnumed.124.269252","article-title":"Clinical trial protocol for LuCAB: a Phase I-II trial evaluating Cabazitaxel in combination with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"66","author":"Kostos","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2026.101293_bib0052","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1200\/JCO.2021.39.15_suppl.5053","article-title":"Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): a phase 1b study","volume":"39","author":"Aggarwal","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101293_bib0053","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2967\/jnumed.120.246041","article-title":"Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer","volume":"62","author":"Czernin","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101293_bib0054","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.7150\/thno.92612","article-title":"PSMA-targeted radiotheranostics in modern nuclear medicine: then, now, and what of the future?","volume":"14","author":"Sallam","year":"2024","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101293_bib0055","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2967\/jnumed.123.266391","article-title":"Differences and common ground in 177Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers","volume":"65","author":"Farolfi","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101293_bib0056","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: a lancet oncology commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101293_bib0057","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2967\/jnumed.122.264298","article-title":"A 2022 international survey on the status of prostate cancer theranostics","volume":"64","author":"Beyer","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101293_bib0058","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","article-title":"Production and regulatory issues for theranostics","volume":"25","author":"Giammarile","year":"2024","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101293_bib0059","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ctarc.2026.101293_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2019.102861","article-title":"ECCO essential requirements for quality cancer care: prostate cancer","volume":"148","author":"Brausi","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:55:41Z","timestamp":1790913341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":60,"alternative-id":["S2468294226002042"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101293","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theranostic strategies in prostate cancer: Advances in PSMA PET imaging and radioligand therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101293"}}